drugset / Trial / NCT05677945

3Mixtatin Versus Modified 3Mix-MP in Lesion Sterilization and Tissue Repair for Treatment of Necrotic Primary Molars

NCT05677945

Unknown 24 enrolled Cairo University
RandomizedParallel-groupTriple-blindTreatment

Summary

This randomized clinical study aims to assess the clinical and radiographic success rate of the 3Mixtatin versus the 3Mix in LSTR in necrotic primary molars.

Timeline

Start
2023-03
Primary completion
2024-03
Completion
2024-08

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Simvastatin Small molecule 2 mg Other
Comparator Cefixime Other / unclassified 200 mg Other
Background Ciprofloxacin Small molecule 500 mg Other
Background Metronidazole Small molecule 500 mg Other

Indications